ProCE Banner Activity

CE / CME

Osteoporosis Pharmacotherapy

Multimedia

In this microlearning module, a leading expert reviews osteoporosis pharmacotherapy options and preferred treatments based on patient-specific factors.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: November 17, 2022

Expiration: November 16, 2023

No longer available for credit.

Share

Faculty

E. Michael Lewiecki

E. Michael Lewiecki, MD

Clinical Assistant Professor of Medicine
Department of Medicine
University of New Mexico School of Medicine
Director
Metabolic Bone Disease
New Mexico Clinical Research & Osteoporosis Center
Albuquerque, New Mexico

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen

Radius Health

Target Audience

This program is intended for primary care physicians and advanced practice providers (nurse practitioners/physician assistants/physician associates).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize key features of pharmacologic treatments for osteoporosis and use this information to customize patient treatment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

E. Michael Lewiecki, MD

Clinical Assistant Professor of Medicine
Department of Medicine
University of New Mexico School of Medicine
Director
Metabolic Bone Disease
New Mexico Clinical Research & Osteoporosis Center
Albuquerque, New Mexico

E. Michael Lewiecki, MD, FACP, FACE: consultant/advisor/speaker: Amgen; researcher: Radius Health.

Planner/Manager Text

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except for Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES, as noted below:

Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES: consultant: Bayer, Novo Nordisk, Provention Bio, Xeris.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until November 16, 2023. PAs should only claim commensurate with the extent of their participation.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 17, 2022, through November 16, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this program is to improve learners’ competence in screening and treating individuals at risk for osteoporosis and address critical gaps in primary and secondary osteoporotic fracture prevention with pharmacotherapy and healthy lifestyle interventions.